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ABSTRACT  
 
The prognosis of patients with blast crisis (BC) chronic myeloid leukemia (CML) is still dismal. 
Allogeneic stem cell transplantation (alloSCT) represents the only curative treatment option, 
but data on transplant outcomes are scarce. We therefore conducted a retrospective, registry based 
study of adult patients allografted for BC CML focusing on patients with active disease at transplant and 
pre-transplant prognostic factors. A total of 170 patients allografted for BC CML after tyrosine kinase 
inhibitor pre-treatment between 2004 and 2016 were analyzed. Prior to transplant, 95 patients were 
in remission, whereas 75 patients had active BC. In multivariable analysis of the entire cohort, 
active BC at transplant was the strongest factor associated with decreased overall survival (OS, 
HR 1.87, P=0.010) and shorter leukemia-free survival (LFS, HR 1.69, P=0.017). For patients 
with BC in remission at transplant, advanced age (≥45 years), lower performance status (≤80%), 
longer interval from diagnosis BC to transplant (>12 months), myeloablative conditioning, and 
unrelated donor (UD) transplant were risk factors for inferior survival. In patients with active 
BC, only UD transplant was significantly associated with prolonged LFS and trended towards 
improved OS. In summary, survival of patients allografted for BC CML was strongly dependent 
on the pre-transplant remission status. In patients with remission of BC, conventional 
prognostic factors remained the major determinants of outcome, whereas in those with active 
BC at transplant, UD transplantation was associated with prolonged LFS in our study. 
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INTRODUCTION 
 
The introduction of tyrosine kinase inhibitors (TKI) has profoundly altered the treatment 
strategy for chronic myeloid leukemia (CML). Targeted therapy with TKI is now considered 
the standard first-line approach for CML patients in all disease stages [1-3]. As a consequence, 
the role and timing of allogeneic stem cell transplantation (alloSCT) in CML, as well as the 
population of patients undergoing allografting have also changed. In the last two decades, the 
number of CML patients receiving alloSCT in first chronic phase (CP1) has rapidly declined 
and nowadays high-risk patients, i.e. at disease stages beyond CP1 or who experienced TKI 
treatment failure, represent the majority of patients referred to alloSCT [4,5]. This is consistent 
with current treatment algorithms that recommend alloSCT for eligible patients who are 
resistant or intolerant to at least one second generation TKI or for patients with blast crisis (BC) 
CML [1].  
The BC of CML fundamentally differs from chronic phase [6,7]. Resembling acute leukemia, 
the CML BC is characterized by substantial alterations in proliferation, differentiation, and 
apoptosis which result in drastic changes in treatment response [7]. Although with the advent 
of TKI the frequency of BC has been greatly reduced compared to the pre-TKI era [8], in 
patients with overt BC, response to TKI-treatment is usually temporary and the prognosis 
remains dismal despite all efforts and progress in drug development [9]. For this group of 
patients alloSCT still represents the only curative treatment option and TKI may provide a 
therapeutic window that permits allografting [4,8,9]. However, in the current TKI era, data on 
transplant outcomes in patients with BC CML, particularly those with active BC at transplant, 
are scarce. Therefore, in the present multicenter, EBMT-registry based study, we 
retrospectively evaluated the outcomes of patients allografted for BC CML focusing on patients 
with active disease at transplant and pre-transplant prognostic factors. 
  
5 
 
PATIENTS AND METHODS  
 
Data source, patient selection and transplant procedure 
This study was based on the registry of the EBMT and was conducted within the Chronic 
Malignancies Working Party (CMWP). The study was approved by the review board of the 
CMWP.  All patients provided informed consent for data collection and analysis. 
Adult patients (≥18 years) reported to have BC CML at transplant (i.e. prior to the start of the 
conditioning) within the EBMT database and who received their first alloSCT from 2004 
through 2016 were identified. Next, study-specific forms were sent to the respective EBMT 
reporting centers to collect additional information including the following: exact disease status 
before start of the conditioning regimen (including blood count, blast count in blood and BM), 
achievement and type of remission with corresponding assessment dates, and the reasons to 
proceed with alloSCT in BC CML.  
Patients were conditioned with myeloablative or non-myeloablative regimens, and received 
methotrexate + calcineurin inhibitor ± other drugs for prophylaxis of graft-versus-host disease 
(GVHD). A total of 170 patients allografted for BC CML between 2004 and 2016 had complete 
data for analysis. These patients were transplanted in 46 centers in 20 countries.  
 
Study endpoints and definitions 
Primary endpoints were overall survival (OS) and leukemia-free survival (LFS) calculated from 
the date of alloSCT to death of any cause or to occurrence of disease relapse or death from any 
cause, respectively. Secondary endpoints were incidence of non-relapse mortality (NRM), 
relapse and GVHD calculated from the date of alloSCT. NRM was defined as death in absence 
of disease relapse. For all endpoints, patients alive were censored at the date of last contact. 
Criteria proposed by the Center for International Blood and Marrow Transplant Research 
(CIBMTR) and ELN criteria were applied for definition of BC CML [1,10]. Remission and 
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relapse of CML was classified in accordance with previous reports [11,12]. Acute GVHD 
(aGVHD) and chronic GVHD (cGVHD) were graded and reported according to the standard 
clinical criteria and in accordance with previous reports [12]. 
 
Statistics 
Variables related to patient, disease, and transplant characteristics were summarized using 
descriptive statistics. Categorical and continuous variables were compared using Fisher's exact 
test and the Mann-Whitney test, respectively. For OS and LFS, survival curves were calculated 
according to the method of Kaplan and Meier (KM); the log-rank test was used to compare 
survival curves. The confidence interval (CI) estimation was performed using Greenwood's 
formula for the variance of the survival function. The follow-up times were calculated by the 
reverse Kaplan-Meier estimate [13].  
NRM and recurrence of the underlying malignancy were considered as competing events. To 
account for the competing risks, cumulative incidence functions were implemented and the 
cumulative incidences were compared using the test of Gray [14-16]. The cumulative 
incidences of GVHD were calculated with death without GVHD as competing event.  
For multivariable analysis of predictors of OS and LFS, and NRM and relapse, Cox proportional 
hazard regression models were performed. Confounding prognostic factors were chosen to 
reflect main transplant characteristics and factors of the established EBMT score [17] and 
covariates associated with OS in univariate analysis. For the full models confounding 
prognostic factors were: patient age, disease status prior to alloSCT, Karnofsky performance 
status (KPS) prior to transplant, interval from BC diagnosis to transplant, year of transplant, 
stem cell source, conditioning intensity, donor type, and donor/recipient sex match. The slim 
models included the covariates: patient age, KPS prior to transplant, interval from BC diagnosis 
to transplant, conditioning intensity and donor type. 
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In order to assess the impact of cGVHD (limited and extensive disease) on LFS, a 6-month 
post-transplant landmark analysis method was applied, i.e. LFS was analyzed in patients who 
had cGVHD versus without cGVHD and who were alive and free of disease at 6 months after 
transplantation. 
Calculations were done using IBM® SPSS® Statistics, Version 24.0.0, and the statistical 
software environment R, version 3.3.2 together with the R packages ‘maxstat’ version 0.7-25, 
‘knitr’ version 1.20, ‘survplot’ version 0.0.7, 'rms' version 5.1-2, ‘cmprsk’ version 2.2-7, 
‘survival’ version 2.42-6. All statistical tests were two-sided. Hazard ratios (HR) were 
estimated with 95%CI. Results with P values <0.05 were considered to be statistically 
significant.  
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RESULTS 
 
Patients 
Between 2004 and 2016, 170 patients with reported BC CML at transplant (i.e. prior to the start 
of the conditioning) met the study eligibility criteria. Type of BC (myeloid or lymphoid) was 
documented for 135 (79%) patients. Prior to transplantation, all patients received TKI therapy 
at some point during the course of the disease (Table 1). In 76% of the patients TKI was 
combined with polychemotherapy. BCR-ABL1 mutations were present in 39 patients; T315I 
was documented in 18 patients. Details on non-T315I mutations and the TKI treatment in 
patients with BCR-ABL1 mutations are summarized in supplementary Table S1 and Table S2, 
respectively. Donor HLA type was available for 74 patients. A total of 19 patients were 
mismatched with the donor. Information on post-transplant interventions, particularly 
administration of TKI or donor lymphocyte infusion (DLI) was not available.  
After thorough analysis of parameters relating to disease status prior to the start of the 
conditioning treatment, a total of 95 (56%) patients had achieved remission of BC CML prior 
to transplant. A total of 66 patients had complete hematologic remission and/or no evidence of 
leukemia, whereas had 29 patients documented complete cytogenetic or major molecular 
response. This patient cohort was termed as BC in remission. Seventy-five (44%) patients had 
active BC CML prior to transplant (termed BC active). Main reason for proceeding with 
alloSCT despite active disease was resistance/refractoriness towards TKI and/or TKI in 
combination with polychemotherapy. Extramedullary disease was documented in 4 patients. 
Median follow-up time was 54.7 months (range 0.1-135.2). Patient, disease and transplant 
characteristics are summarized in Table 1.  
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Outcomes 
A total of 54 patients experienced aGVHD of any grade post-transplant. The cumulative 
incidences of any grade aGVHD and grade 3-4 aGVHD at day+100 were 26.3% (95% CI 19.9-
33.2) and 11.0% (95% 6.8-16.3), respectively. A total of 60 patients experienced cGVHD after 
alloSCT (limited and extensive in 30 patients each). Cumulative incidence of cGVHD (limited 
and extensive) at 1-year was 32.9% (95% CI 25.8-40.3). 
The response after alloSCT was reported for a total of 157 patients with 91 patients (58%) 
having documented major molecular response post-transplant. By the time of analysis, a total 
of 103 patients had died, 41 of NRM and 62 due to disease progression. A total of 84 patients 
experienced CML relapse post-transplant including both hematologic and molecular relapse 
only. 
For the entire patient cohort, OS at 1 and 3 years after alloSCT was 57.5% (95% CI 50.1-64.9) 
and 38.5% (95% CI 30.7-46.3), respectively. The estimated probability of LFS was 34.6% (95% 
CI 27.3-41.9) and 26.1% (95% CI 19.2-33.0) at 1 and 3 years after alloSCT, respectively. The 
cumulative incidence of relapse at 1 and 3 years after alloSCT was 45.7% (95% CI 38.0-53.1) 
and 50.7% (95% CI 42.6-58.1), respectively, and the cumulative incidence of NRM at 1 and 3 
years after alloSCT was 19.7% (95% CI 14.1-26.1) and 23.3% (95% CI 17.1-30.1), 
respectively.  
 
Prognostic factors 
With regard to the primary endpoints, in univariable analyses of the entire cohort, only low KPS 
(≤80%) and active BC at transplant were significantly associated with both worse OS and 
shorter LFS after alloSCT. For both covariates, the adverse impact on survival was based on a 
trend towards higher risk or relapse rather than NRM. Results of the univariate analyses are 
summarized in Table 2. 
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In multivariable analyses, active BC at transplant was significantly associated with both 
decreased OS (HR 1.87, P=0.010) and shorter LFS (HR 1.69, P=0.017). Other covariates 
showing associations with outcome were low KPS (shorter OS and LFS) and early year of 
transplant (≤2010, higher risk of NRM). Results of the multivariable analyses of the entire 
patient cohort are given in Table 3. 
Accordingly, for patients who received alloSCT in active BC probability of OS and LFS post-
transplant was significantly lower as compared to patients allografted for BC in remission 
(P<0.001 and P=0.001, respectively) (Figure 1A and B). Again, worse survival of patients 
transplanted in active disease was rather due to a trend towards higher incidence of relapse 
(P=0.076) (Figure 1C) than NRM (P=0.190) (Figure 1D). The incidences of acute and chronic 
GVHD were similar between the cohorts. The same is true for the documented post-transplant 
molecular response rates (56% and 60%).   
Consequently, prognostic factors for survival were analyzed separately according to disease 
status at alloSCT. For this purpose, due to the lower number of events in each cohort slim 
models were applied. For patients with BC in remission at transplant advanced age, lower KPS, 
longer interval from diagnosis of BC to transplant, myeloablative conditioning, and UD 
transplant were risk factors for inferior survival with the latter two being associated with a 
higher risk of NRM (Table 4). In contrast, in patients allografted for active BC, only transplant 
from an unrelated donor (UD) was significantly associated with prolonged LFS and trended 
towards improved OS (Table 5).  
 
Impact of cGVHD on outcome 
To evaluate the impact of cGVHD (both extensive and limited disease) on LFS (entire cohort 
and in the subgroups according to the disease status at alloSCT) a 6-month landmark analysis 
was performed, grouping patients with respect to prior history of cGVHD. A total of 85 patients 
fulfilled the conditions of being alive and in remission at 6 months post-transplant. There was 
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no significant association of prior cGVHD with LFS in all cohorts analyzed. Specifically, in 
the entire cohort and the subgroup of patients with active BC at transplant survival rates of 
patients with and without prior history of cGVHD were very similar (Figure 2A and B). In 
contrast, in patients allografted for BC in remission, the 3-year LFS rates of patients with and 
without prior history of cGVHD were 83% and 50%, respectively, however, not reaching 
statistical significance (Figure 2C). 
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DISCUSSION 
 
The BC remains the major challenge in the management of CML [8]. This is mainly due to the 
fact that in patients with BC CML, even after alloSCT long-term outcomes are rarely achieved 
[18]. For CML in general, the disease and transplant risks that primarily influence patient 
outcome are well defined and can be captured by the EBMT score [17]. The assessment of both 
has become standard and with improved supportive care and patient selection NRM has 
substantially declined over time [4]. However, this is not true for patients with high transplant 
risk [19] and survival outcomes of patients with high transplant risk allografted for advanced 
and/or refractory CML remains particularly poor [20].  
In the current TKI (pre-treatment) era, the definition of prognostic factors for transplant 
outcomes in BC CML has been hampered by relative small patient numbers. In the study of 
Oyekunle et al. [21], which evaluated the outcomes of 68 patients (including 8 with BC), 
advanced phase (>CP1) disease, was associated with adverse overall and relapse-free survival 
(47% and 32% at 2-years, respectively). In another smaller study on 63 patients (28 with active 
disease at transplant), the 2-year incidence of relapse was 38% with disease status at transplant 
together with the EBMT score being the major factors influencing transplant outcome [22]. In 
the last and so far largest CIBMTR-based registry study published in 2012, a total of 449 
patients allografted between 1999 and 2004 were analyzed including 80 patients with 
documented BC at the start of conditioning, 37 of whom had previous TKI treatment [23]. With 
an estimated 1- and 3-year OS of 30% and <20%, respectively, the post-transplant outcome for 
this group of patients was particularly poor. By comparison, in the 23 patients with prior history 
of BC, who achieved remission after TKI therapy, survival rates of 61% and 41% (at 1- and 3-
years, respectively) could be estimated [23]. Prognostic factors significantly associated with 
both OS and LFS in this study were lower KPS (<80%) and longer interval from diagnosis to 
transplant (>12 months), whereas no impact of pre-transplant imatinib use was observed [23].  
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In our study, and in accordance with previous reports [21,22], active disease at transplant was 
the strongest factor associated with worse post-transplant survival. This was based on a trend 
towards higher risk of relapse rather than NRM. For patients who achieved remission prior to 
alloSCT, previously reported [23] and well-recognized [17] prognostic factors were the main 
determinants of post-transplant survival. Interestingly, in this group of patients, reduced 
intensity conditioning (RIC) was associated with improved outcome due to lower risk of NRM 
as revealed by the multivariable models. This contrasts with previous studies that show 
comparable transplant outcomes after myeloablative conditioning and RIC in patients with 
advanced phase CML [23], and overall post-transplant survival to be primarily influenced by 
the EBMT score and less by the choice of the conditioning regimen [24]. However, although 
larger retrospective series failed to confirm superiority of RIC, a potential advantage of RIC 
due to lower early NRM particularly for patients with advanced age and co-morbidities can 
probably be assumed [4]. 
For patients with active BC at transplant, UD transplantation showed an association with 
improved LFS in our series. In this patient cohort, data on donor HLA type were available for 
31 patients, of whom only 8 patients were mismatched with the donor. Therefore, further 
analyses with regard to HLA-matching were precluded by the small sample size. The reasons 
for this association are not clear, particularly since there is no correlation with relapse or NRM. 
One could hypothesize, that patients with active BC may benefit from an UD transplant because 
of a stronger graft-versus-leukemia (GVL) effect. However, a previous large registry study 
failed to demonstrate so [25]. Plus, generally, sensitivity to GVL is thought to be more 
pronounced in patients allografted for chronic phase or rather less advanced CML [26]. 
It has been long recognized, that GVL is related to cGVHD, which exerts anti-leukemic effects, 
and thus contributes to improved survival after alloSCT [27]. This is particularly true for 
patients allografted for CML [28]. In our patients, the incidences of acute and chronic GVHD 
were comparable to previous reports [22,23]. However, in all cohorts analyzed, no significant 
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association of prior cGVHD with LFS was observed. As already stated above, the reason is 
probably related to the fact that the GVL effect is rather weak in BC CML [26]. This also might 
explain that, albeit not significant, effects of prior cGVHD on LFS were only detectable in 
patients allografted in remission of BC CML.   
Our study has several limitations that need to be addressed. First, as with all registry-based 
retrospective cohort studies, a selection bias cannot be ruled out. Second, there was a 
considerable proportion of missing values in the EBMT database and incomplete reporting of 
requested data particularly in terms of presence of BCR-ABL1 mutations, type of BC and 
reasons to proceed with alloSCT despite active disease. In addition, no data on the clinical CML 
scores at diagnosis and the duration of previous disease stages and treatment was accessible for 
analysis. Further, since prognostic factors of survival outcomes were the focus of the present 
study, information on post-transplant interventions (DLI and particularly post-transplant TKI 
treatment) was also not available. Finally, one could argue that most patients in our study were 
in disease remission, which may not necessarily reflect actual BC of CML. However, with 
regard to the latter, it should be noted that even in remission the gene expression signatures of 
the BC and hence the adverse biology are retained [7,29]. In the transplant setting, this might 
explain why long-term outcomes are only rarely achieved [18,23]. It can be expected that in the 
near future, eligible patients with BC CML will continue to be considered candidates for 
alloSCT. Based, to the best of our knowledge, on one of the largest cohort of patients with BC, 
the present study provides an update on the efficacy of alloSCT for BC CML in the TKI era 
and may help select patients most likely to benefit from this treatment approach.  
In conclusion, survival of patients allografted for BC CML remains poor in the TKI era unless 
disease remission could be achieved, but even so, survival is far worse compared to patients 
transplanted in CP1. Therefore, for physicians following CP CML patients under TKI it is of 
utmost importance to avoid evolution to BC and to consider alloSCT prior to overt disease 
progression. This means that patients under TKI should be referred early to a transplant center, 
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particularly when there is evidence for molecular progression after two or three lines of TKI 
therapy. In patients with BC CML who achieve remission prior to transplantation, conventional 
and well-recognized prognostic indicators remain the main determinants of survival outcomes, 
whereas in those with active BC at transplant, UD transplantation is associated with a survival 
advantage.  
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Table 1. Patient, disease and transplant characteristics.  
 N=170 
Parameter  
Age [years] at alloSCT (median, range) 44 (18-75) 
Patient sex, n (%) 
   Male 
   Female 
 
119 (70) 
51 (30) 
Disease status at alloSCT, n (%) 
   BC in remission 
   BC active 
 
95 (56) 
75 (44) 
Type of BC, n (%) 
   Myeloid 
   Lymphoid 
   Unknown 
 
88 (52) 
47 (28) 
35 (21) 
Karnofsky performance status, n (%) 
   >80% 
   ≤80% 
   Unknown 
 
111 (65) 
51 (30) 
8 (5) 
TKI pre-treatment, n (%) 
   1 TKI 
   1st generation* 
   2nd generation† 
   3rd generation‡ 
   2 TKI 
   1st / 2nd generation 
   1st / 3rd generation 
   2nd / 3rd generation 
   3 or more TKI 
   1st / 2nd generation 
   2nd / 3rd generation 
   1st / 2nd / 3rd generation 
 
100 (59) 
73 (43) 
26 (15) 
1 (1) 
56 (33) 
51 (30) 
2 (1) 
3 (2) 
14 (8) 
3 (2) 
1 (1) 
10 (6) 
Additional cytogenetic aberrations, n (%) 
   Present 
   Absent 
   Unknown 
 
30 (18) 
109 (64) 
31 (18) 
BCR-ABL1 mutations, n (%) 
   T315I 
   Other than T315I 
   No 
   Unknown 
 
18 (11) 
21 (12) 
2 (1) 
129 (76) 
Interval diagnosis of BC to transplant, n 
(%) 
   ≤12 months 
   >12 months 
 
73 (43) 
97 (57) 
Year of transplant, n (%) 
   ≤2010 
   >2010 
 
74 (44) 
96 (56) 
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Table 1. continued  
 N=170 
Parameter  
Stem cell source, n (%) 
   PB 
   BM 
   CB 
 
145 (85) 
18 (11) 
7 (4) 
Conditioning, n (%) 
   MAC 
   RIC 
 
108 (64) 
62 (36) 
Donor, n (%) 
   Unrelated 
   Related 
 
91 (54) 
79 (46) 
Recipient – donor sex match, n (%) 
   Matched 
   Male – female 
   Female – male  
   Unknown 
 
101 (59) 
39 (23) 
27 (16) 
3 (2) 
 
Abbreviations: CB, cord blood; BC, blast crisis; BM, bone marrow; CI, confidence interval; HR, hazard ratio; 
MAC, myeloablative conditioning; OS, overall survival; PB, peripheral blood; PFS, progression-free survival; 
RIC, reduced intensity conditioning; TKI, tyrosine kinase inhibitor. 
* imatinib, † dasatinib or nilotinib or bosutinib, ‡ ponatinib. 
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Table 2. Prognostic factors of overall and leukemia-free survival and relapse and non-relapse mortality (entire cohort, univariate analysis). 
 
Covariate 
 
Effect 
OS† LFS‡ Relapse¶ NRM§ 
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P 
Patient age ≥45 years 1.23 0.84-1.82 0.286 1.20 0.84-1.70 0.318 1.32 0.86-2.02 0.201 0.92 0.50-1.68 0.770 
Patient sex Female 1.02 0.67-1.54 0.941 1.13 0.78-1.65 0.522 1.46 0.93-2.29 0.097 0.68 0.34-1.37 0.280 
Disease status BC active 2.00 1.35-2.96 0.001 1.80 1.27-2.57 0.001 1.48 0.97-2.27 0.068 1.50 0.82-2.75 0.191 
Type of BC Myeloid 1.05 0.66-1.66 0.844 1.15 0.75-1.74 0.528 1.88 1.12-3.16 0.017 0.49 0.24-0.98 0.044 
Karnofsky performance 
status 
 
≤80% 
 
1.96 
 
1.30-2.98 
 
0.001 
 
1.95 
 
1.34-2.86 
 
0.001 
 
1.58 
 
0.98-2.56 
 
0.061 
 
1.33 
 
0.70-2.55 
 
0.392 
TKI pre-treatment >1 TKI 0.65 0.41-1.03 0.067 0.79 0.52-1.20 0.261 1.35 0.82-2.23 0.250 0.32 0.14-0.74 0.008 
Additional cytogenetic 
aberrations 
 
Absent 
 
1.26 
 
0.72-2.22 
 
0.416 
 
0.82 
 
0.51-1.30 
 
0.392 
 
0.57 
 
0.34-0.99 
 
0.046 
 
1.87 
 
0.68-3.50 
 
0.221 
T315I mutation Absent 0.43 0.18-1.02 0.055 0.55 0.27-1.12 0.101 0.81 0.37-1.81 0.620 0.44 0.11-1.75 0.240 
Interval diagnosis of 
BC to transplant 
 
≤12 months 
 
0.81 
 
0.55-1.21 
 
0.302 
 
0.86 
 
0.60-1.23 
 
0.408 
 
0.93 
 
0.61-1.43 
 
0.761 
 
0.86 
 
0.46-1.59 
 
0.630 
Year of transplant ≤2010 1.64 1.11-2.43 0.013 1.39 0.97-1.97 0.073 0.84 0.54-1.29 0.420 2.92 1.53-5.59 0.001 
Stem cell source PB  0.76 0.45-1.27 0.292 1.05 0.64-1.73 0.852 1.46 0.78-2.77 0.240 0.65 0.30-1.43 0.292 
Conditioning RIC 0.88 0.59-1.32 0.530 0.99 0.69-1.43 0.963 1.39 0.91-2.14 0.131 0.52 0.25-1.05 0.069 
Donor Unrelated 1.08 0.73-1.59 0.701 0.92 0.65-1.31 0.634 0.95 0.62-1.46 0.822 0.99 0.54-1.81 0.960 
Recipient – donor sex 
match 
 
RMDF 
 
1.04 
 
0.65-1.66 
 
0.860 
 
0.92 
 
0.60-1.41 
 
0.698 
 
0.83 
 
0.49-1.41 
 
0.490 
 
1.16 
 
0.57-2.36 
 
0.680 
 
†Number of events: 103; ‡Number of events: 125; ¶Number of events: 84; §Number of events: 41. 
 
Abbreviations: BC, blast crisis; CI, confidence interval; HR, hazard ratio; LFS, leukemia-free survival; NRM, non-relapse-mortality; OS, overall survival; PB, peripheral blood; 
RIC, reduced intensity conditioning; RMDF, recipient male – donor female; TKI, tyrosine kinase inhibitor. 
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Table 3. Multivariable analysis overall and leukemia-free survival and relapse and non-relapse mortality (entire cohort, complete case 
analysis, n=159). 
 
Covariate 
 
Effect 
OS† LFS‡ Relapse¶ NRM§ 
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P 
Patient age ≥45 years 1.25 0.79-1.99 0.345 1.09 0.71-1.68 0.690 1.13 0.65-1.95 0.660 1.16 0.51-2.61 0.730 
Disease status BC active 1.87 1.16-3.00 0.010 1.69 1.10-2.59 0.017 1.33 0.75-0.81 0.260 1.69 0.73-3.91 0.220 
Karnofsky performance 
status 
 
≤80% 
 
1.82 
 
1.10-3.01 
 
0.019 
 
1.65 
 
1.05-2.59 
 
0.029 
 
1.50 
 
0.85-2.63 
 
0.160 
 
1.23 
 
0.54-2.80 
 
0.630 
Interval diagnosis of 
BC to transplant 
 
≤12 months 
 
0.79 
 
0.51-1.22 
 
0.290 
 
0.78 
 
0.52-1.17 
 
0.231 
 
0.82 
 
0.50-1.35 
 
0.440 
 
0.95 
 
0.48-1.88 
 
0.880 
Year of transplant ≤2010 1.27 0.83-1.95 0.276 1.09 0.73-1.61 0.687 0.70 0.42-1.18 0.180 2.59 1.33-5.06 0.005 
Stem cell source PB  0.67 0.37-1.22 0.189 0.99 0.57-1.72 0.970 1.41 0.66-2.99 0.380 0.60 0.22-1.64 0.320 
Conditioning RIC 0.65 0.39-1.07 0.092 0.83 0.52-1.30 0.410 1.12 0.65-1.94 0.680 0.53 0.78-4.65 0.160 
Donor Unrelated 1.13 0.71-1.82 0.605 0.86 0.57-1.31 0.486 0.94 0.57-1.56 0.820 1.04 0.46-2.36 0.930 
Recipient – donor sex 
match 
 
RMDF 
 
1.07 
 
0.66-1.76 
 
0.778 
 
0.96 
 
0.61-1.51 
 
0.855 
 
0.92 
 
0.51-1.68 
 
0.790 
 
0.94 
 
0.44-2.02 
 
0.880 
 
†Number of events: 93; ‡Number of events: 115; ¶Number of events: 78; §Number of events: 37. 
 
Abbreviations: BC, blast crisis; CI, confidence interval; HR, hazard ratio; LFS, leukemia-free survival; NRM, non-relapse-mortality; OS, overall survival; PB, peripheral blood; 
RIC, reduced intensity conditioning; RMDF, recipient male – donor female. 
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Table 4. Multivariable analysis overall and leukemia-free survival and relapse and non-relapse mortality in patients with CML blast crisis 
in remission at transplant (slim model, complete case analysis, n=88). 
 
Covariate 
 
Effect 
OS† LFS‡ Relapse¶ NRM§ 
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P 
Patient age ≥45 years 2.42 1.13-5.14 0.022 2.51 1.30-4.83 0.006 1.40 0.67-2.95 0.370 2.72 0.93-7.94 0.067 
Karnofsky performance 
status 
 
≤80% 
 
2.69 
 
1.26-5.76 
 
0.011 
 
2.83 
 
1.46-5.49 
 
0.002 
 
2.18 
 
0.98-4.87 
 
0.057 
 
0.94 
 
0.22-3.94 
 
0.930 
Interval diagnosis of 
BC to transplant 
 
≤12 months 
 
0.48 
 
0.24-0.94 
 
0.033 
 
0.57 
 
0.32-1.00 
 
0.052 
 
0.67 
 
0.33-1.36 
 
0.270 
 
0.90 
 
0.31-2.61 
 
0.850 
Conditioning RIC 0.26 0.11-0.65 0.004 0.40 0.19-0.84 0.016 1.25 0.57-2.75 0.570 0.09 0.02-0.44 0.003 
Donor Unrelated 3.61 1.72-7.58 0.001 1.81 0.99-3.31 0.053 0.78 0.39-1.54 0.470 4.41 1.51-12.86 0.007 
 
†Number of events: 39; ‡Number of events: 54; ¶Number of events: 37; §Number of events: 17. 
 
Abbreviations: BC, blast crisis; CI, confidence interval; CML, chronic myeloid leukemia; HR, hazard ratio; LFS, leukemia-free survival; NRM, non-relapse-mortality; OS, overall 
survival; PB, peripheral blood; RIC, reduced intensity conditioning; RMDF, recipient male – donor female. 
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Table 5. Multivariable analysis overall and leukemia-free survival and relapse and non-relapse mortality in patients with active blast crisis 
CML at transplant (slim model, complete case analysis, n=74). 
 
Covariate 
 
Effect 
OS† LFS‡ Relapse¶ NRM§ 
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P 
Patient age ≥45 years 0.85 0.46-1.55 0.589 0.59 0.33-1.04 0.068 0.98 0.51-1.90 0.960 0.75 0.28-2.02 0.571 
Karnofsky performance 
status 
 
≤80% 
 
1.47 
 
0.78-2.79 
 
0.233 
 
1.35 
 
0.76-2.37 
 
0.305 
 
1.03 
 
0.54-1.96 
 
0.918 
 
1.25 
 
0.43-3.65 
 
0.680 
Interval diagnosis of 
BC to transplant 
 
≤12 months 
 
0.84 
 
0.48-1.46 
 
0.530 
 
0.84 
 
0.48-1.45 
 
0.528 
 
1.03 
 
0.53-1.98 
 
0.938 
 
0.75 
 
0.32-1.79 
 
0.522 
Conditioning RIC 0.75 0.41-1.35 0.338 1.03 0.58-1.82 0.931 1.22 0.59-2.52 0.600 0.71 0.29-1.78 0.473 
Donor Unrelated 0.56 0.31-1.01 0.055 0.47 0.27-0.81 0.007 1.07 0.53-2.15 0.850 0.48 0.19-1.24 0.130 
 
†Number of events: 57; ‡Number of events: 64; ¶Number of events: 42; §Number of events: 22. 
 
Abbreviations: BC, blast crisis; CI, confidence interval; CML, chronic myeloid leukemia; HR, hazard ratio; LFS, leukemia-free survival; NRM, non-relapse-mortality; OS, overall 
survival; PB, peripheral blood; RIC, reduced intensity conditioning; RMDF, recipient male – donor female. 
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FIGURE LEGENDS 
 
Figure 1. Overall survival (OS), leukemia-free survival (LFS) and cumulative incidences 
of relapse and non-relapse mortality (NRM) in patients transplanted in active BC CML 
(n=75) versus patients allografted for BC CML in remission (n=95). 
(A) For patients who were allografted for active BC, the 3-year estimated probability of post-
transplant OS was 23.8% (95% CI 13.6-34.0) as compared to 51.1% (95%CI 40.5-61.7) for 
patients who received alloSCT in remission of BC CML (P<0.001, log-rank test for the total 
observation time). 
(B) The estimated probability of LFS at 3 years post-transplant in patients transplanted for 
active BC versus BC in remission was 11.6% (95% CI 3.0-20.2) versus 33.8% (95% CI 23.6-
44.0), respectively (P=0.001, log-rank test for the total observation time). 
(C) For patients who received allografts in active BC, the 3-year cumulative incidence of 
relapse after alloSCT was 56.4% (95% CI 44.1-66.9) as compared to 45.9% (95% CI 35.1-56.1) 
for patients who were allografted for BC in remission (P=0.076, Gray’s test). 
(D) The 3-year cumulative incidence of NRM post-transplant in the active BC cohort versus 
the BC in remission cohort was 27.1% (95% CI 17.4-37.7) and 20.2% (95% CI 12.5-29.3), 
respectively (P=0.190, Gray’s test). 
 
Figure 2. Kaplan-Meier estimates of leukemia-free survival based on a landmark analysis 
at 6 months post-transplant, grouping patients according to prior history of chronic 
GVHD. 
(A) In the entire cohort (n=85), the survival rates of patients with and without prior history of 
cGVHD were similar (at 3-years: 55.4% 95% CI 35.6-75.2 versus 48.0% 95% CI 34.7-61.3). 
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(B) When regarding the subgroup of patients with active BC at transplant (n=31), the 3-year 
LFS rates of patients with and without prior history were 30.8% (95% CI 5.7-55.9) and 43.2% 
(95% CI 19.9-66.5), respectively. 
(C) In the subgroup of patients with BC in remission at alloSCT (n=54), the 3-year LFS rates 
of patients with and without prior history were 83.3% (95% CI 62.1-100.0) and 49.8% (95% 
CI 33.3-66.3), respectively. 
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